The PODXL2 Polyclonal Antibody (PAC011336) is a valuable tool for research involving PODXL2, a cell surface protein associated with cancer progression and metastasis. This antibody, generated in rabbits, exhibits high reactivity with human samples and has been validated for use in various applications, including Western blotting.PODXL2, also known as podocalyxin-like protein 2, is a key player in tumor invasion and metastasis, making it a promising target for cancer research. Its expression has been linked to aggressive phenotypes in multiple cancer types, suggesting its potential as a diagnostic marker or therapeutic target.
The PODXL2 Polyclonal Antibody enables detection and analysis of PODXL2 in cancer cells, providing valuable insights for studies in oncology and cell biology.Understanding the role of PODXL2 in cancer progression is essential for developing effective strategies to target metastasis and improve patient outcomes. The PODXL2 Polyclonal Antibody offers researchers a reliable tool for investigating the function of PODXL2 and its potential as a therapeutic target in cancer treatment.
PODXL2: Acts as a ligand for vascular selectins. Mediates rapid rolling of leukocytes over vascular surfaces through high affinity divalent cation-dependent interactions with E-, P- and L- selectins. Belongs to the podocalyxin family. 2 isoforms of the human protein are produced by alternative splicing.Protein type: Membrane protein, integral; Cell adhesionChromosomal Location of Human Ortholog: 3q21.3Cellular Component: integral to plasma membraneMolecular Function: glycosaminoglycan binding; protein bindingBiological Process: leukocyte tethering or rolling
UniProt Protein Details:
NCBI Summary:
This gene is a member of the CD34 family of cell surface transmembrane proteins, which are characterized by an N-terminal extracellular mucin domain, globular and stalk domains, a single pass transmembrane region, and a charged cytoplasmic tail. The encoded protein is a ligand for vascular selectins. [provided by RefSeq, Oct 2012]
